Voyager Therapeutics Inc is a pioneering biotechnology firm dedicated to developing gene therapies for neurological diseases. With a focus on Alzheimer's disease, their leading project involves VY-TAU01, an innovative anti-tau antibody treatment. Their research extends to potential therapies for amyotrophic lateral sclerosis, Friedreich’s ataxia, Parkinson’s disease, and Huntington’s disease, all in various stages of preclinical trials. Based in Lexington, Massachusetts, Voyager Therapeutics collaborates with notable industry partners like Alexion and Novartis to advance their mission of tackling some of the most challenging neurological disorders.
On the June 30 episode of Mad Money, a 23-year-old caller named Jackson from Iowa asked Jim Cramer about Voyager Therapeutics (NASDAQ:VYGR), a clinical-stage gene therapy company he wanted to hold for…
Omor Ibne Ehsan 